|Bid||1.40 x 1000|
|Ask||1.80 x 2000|
|Day's Range||1.55 - 1.60|
|52 Week Range||1.30 - 6.11|
|PE Ratio (TTM)||-2.62|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that Titan President and CEO Sunil Bhonsle will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, Sept. 27 at 9:45 a.m. EDT at the Intercontinental New York Barclay Hotel. Mr. Bhonsle will review the company's ProNeura-based pipeline of clinical and early-stage product candidates, as well as provide a market update on Probuphine for the maintenance treatment of opioid dependence.
SOUTH SAN FRANCISCO, Calif., Aug. 24, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its ropinirole implant intended for treatment of the signs and symptoms of Parkinson's disease. "New treatments that offer continuous delivery of medication providing non-pulsatile stimulation of dopamine receptors in the brain appear to have some advantages over oral formulations," said Dr. Aaron Ellenbogen of the Michigan Institute of Neurological Disorders, and the principal investigator at the first trial site, near Detroit, Michigan.
Q2 2017 Titan Pharmaceuticals Inc Earnings Call